Articles From: AmEx, JetBlue End Co-Branded Credit Card -- Update to Amica Mature Lifestyles to Announce Second Quarter Results and Host Conference Call January 14, 2015


2015/2/13
By Robin Sidel American Express Co.
Sign-up for AmEx, JetBlue End Co-Branded Credit Card -- Update investment picks
2015/2/13
By Robin Sidel American Express Co.
Sign-up for AmEx, JetBlue End Co-Branded Credit-Card Deal investment picks
2014/12/26
Affiliated Managers Group, Inc. (NYSE: AMG) today announced the completion of its additional investment in AQR Capital Management, LLC, a leading global investment manager.
Sign-up for AMG Completes Investment in AQR Capital Management investment picks
2014/12/17
Affiliated Managers Group, Inc. (NYSE: AMG) today announced it has agreed to a transaction which will result in a meaningful increase in its minority investment in AQR Capital Management, LLC, a leading global investment manager and an AMG Affiliate since 2004.
Sign-up for AMG Increases its Investment in AQR Capital Management investment picks
2015/1/27
Affiliated Managers Group, Inc. (NYSE: AMG) today reported its financial and operating results for the fourth quarter and full year 2014.
Sign-up for AMG Reports Financial and Operating Results for the Fourth Quarter and Full Year 2014 investment picks
2015/1/20
Affiliated Managers Group, Inc. (NYSE: AMG) will report financial and operating results for the fourth quarter and full year ended December 31, 2014 on Tuesday, January 27, 2015.
Sign-up for AMG to Announce Fourth Quarter and Full Year Results on January 27, 2015 investment picks
2015/1/27
AMG Wealth Partners, LP, a subsidiary of Affiliated Managers Group, Inc. (NYSE: AMG), has entered into a definitive agreement to acquire a majority equity interest in Baker Street Advisors LLC (“Baker Street”). After the closing of the transaction, the management partners of Baker Street will continue to hold a substantial portion of the equity of the business and direct its day-to-day operations.
Sign-up for AMG Wealth Partners Announces Investment in Baker Street Advisors investment picks
2014/12/11
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif.
Sign-up for Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
2015/1/5
Alliance Combines Amgen's Oncology Targets and Kite's Leading CAR T Cell Therapy Platform to Develop new Therapeutic Candidates Kite to Receive a $60 Million Upfront Payment From Amgen and Eligible for up to $525 Million in Regulatory and Sales Milestone Payments per Amgen Program; Plus, Tiered High Single- to Double-Digit Royalties for Sales and License of Kite's Intellectual Property for CAR T Cell Products Amgen Eligible to Receive up to $525 Million in Milestone Payments per Kite Program; Plus, Tiered Single-Digit Sales Royalties Kite to Host Conference Call Today at 4:00 PM Eastern Time THOUSAND OAKS, Calif.
Sign-up for Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies investment picks
2015/1/5
By Tess Stynes Amgen Inc. and Kite Pharma Inc. reached a research collaboration and license agreement to develop cancer immunotherapy treatments that focus on Amgen's array of cancer targets and Kite Pharma's autologous cell therapy platform.
Sign-up for Amgen and Kite Pharma in cancer immunotherapy pact investment picks
2015/1/12
MD Anderson's Moon Shots Program key to Collaboration THOUSAND OAKS, Calif.
Sign-up for Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome investment picks
2014/12/6
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Overall Response Rate, Duration of Response, Health-Related Quality of Life Secondary Endpoints Met; Overall Survival Continues to be Monitored Results to be Presented During an Oral Session at ASH on Sunday, December 7 at 12 p.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 8 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma investment picks
2014/12/17
THOUSAND OAKS, Calif.
Sign-up for Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend investment picks
2014/12/6
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle Results to be Presented During an Oral Session at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday, December 8 at 10:30 a.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 10 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease investment picks
2015/2/3
Primary Efficacy Analysis Demonstrates Clinical Equivalence Second Positive Phase 3 Study for Amgen's ABP 501 THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis investment picks
2015/1/22
THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results investment picks
2014/12/22
Sponsorship Secures Resources Needed for Biotech Startups to Advance Innovative Research CAMBRIDGE, Mass.
Sign-up for Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts investment picks
2014/12/8
Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif.
Sign-up for Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia investment picks
2015/1/15
Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab Separate Analysis of Phase 3 Trial Demonstrates no Differences in Quality of Life Between FOLFOX Regimens With or Without Vectibix THOUSAND OAKS, Calif.
Sign-up for Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer investment picks
2015/1/27
By Tess Stynes Amgen Inc. said fourth-quarter earnings rose about 27%, as sales growth was again driven by key drugs such as cancer therapy Kyprolis and osteoporosis treatment Prolia.
Sign-up for Amgen Profit Rises 27% on Higher Sales of Key Drugs investment picks
2015/1/27
By Tess Stynes And Jonathan D.
Sign-up for Amgen Profit Rises 27% on Higher Sales of Key Drugs -- Update investment picks
2015/1/27
US Submission Designed to Support Conversion From Accelerated to Full FDA Approval and Expansion of Current Approved Indication EMA Grants Kyprolis Accelerated Assessment and Orphan Drug Designation THOUSAND OAKS, Calif.
Sign-up for Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma investment picks
2015/1/8
THOUSAND OAKS, Calif.
Sign-up for Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference investment picks
2014/12/3
THOUSAND OAKS, Calif.
Sign-up for Amgen To Webcast Investor Meeting At Upcoming American Society of Hematology (ASH) 56th Annual Meeting And Exposition investment picks
2015/1/29
FIND FH Initiative Unites Industry, Advocacy Community and Academia in an Effort to Support People Affected by Familial Hypercholesterolemia (FH), a Serious Genetic Disorder THOUSAND OAKS , Calif., SOUTH PASADENA , Calif.
Sign-up for Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH™ Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia investment picks
2015/1/27
2014 GAAP EPS Were $6.70 2015 Revenues and Adjusted EPS Reaffirmed to be in the Range of $20.8-$21.3 Billion and $9.05-$9.40, Respectively THOUSAND OAKS, Calif.
Sign-up for Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70 investment picks
2015/2/13
(TSX Symbol: ACC) – Amica Mature Lifestyles Inc. (“Amica” or the “Company”) announced today that Colin Halliwell, Amica’s Chief Operating Officer (“COO”) has decided to retire from the Company effective September 1, 2015.
Sign-up for Amica Mature Lifestyles Announces Retirement of Chief Operating Officer investment picks
2015/1/14
(TSX Symbol: ACC) – Amica Mature Lifestyles Inc. (“Amica” or the “Company”) is pleased to announce the Company’s operating and financial results for the three and six months ended November 30, 2014.
Sign-up for Amica Mature Lifestyles Announces Second Quarter Fiscal 2015 Results and Quarterly Dividend investment picks
2014/12/4
(TSX Symbol: ACC) – Amica Mature Lifestyles Inc. (“Amica” or the “Company”) announced today that it will be releasing its second quarter results on Wednesday, January 14, 2015, before the market opens.
Sign-up for Amica Mature Lifestyles to Announce Second Quarter Results and Host Conference Call January 14, 2015 investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: AmEx, JetBlue End Co-Branded Credit Card -- Update to Amica Mature Lifestyles to Announce Second Quarter Results and Host Conference Call January 14, 2015
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent